By attending this webinar, you will learn:
• Insights into Touchlight’s cell-free DNA platform, including R&D and GMP manufacturing capabilities, and experience in supporting advanced therapy clinical programmes.
• How Doggybone DNA (dbDNA™) can increase AAV genome titres, improve full capsid percentages, and reduce impurity packaging.
• How Pharmaron’s scalable AAV platform enables seamless progression from early feasibility studies through manufacturing.
• The value of leveraging small-scale upstream models to accelerate process development while maintaining scalability.
• How collaboration with innovators and technology providers helps drive continuous platform evolution.
• A case study highlighting the impact of this collaborative, innovation-driven approach on AAV process development.
